FIELD: diagnostics methods; satisfaction of human vital needs.
SUBSTANCE: present invention relates to a method for diagnosing lipidemia by laboratory analysis of blood lipids before treating lipidemia with subsequent determination of atherogenicity coefficient, characterized by that before diagnosing lipidemia, triacylglycerol is assessed additionally, the relation (TCS+TAG)/CS HDL is determined, and if the ratio is increased to 4.1 standard units or more, the lipidemia is diagnosed.
EFFECT: high accuracy and effectiveness of diagnosing lipidemia less labor-intensive method, which does not require high material costs.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING THE EFFECTIVENESS OF THE TREATMENT OF LIPIDEMIA | 2019 |
|
RU2694534C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF LIPIDEMIA | 2019 |
|
RU2714689C1 |
| DIAGNOSTIC TECHNIQUE FOR EARLY AND LATE STAGES OF LIPIDEMIA | 2019 |
|
RU2694538C1 |
| METHOD FOR PREDICTION OF POSSIBLE THROMBOGENIC COMPLICATIONS IN ATHEROGENIC GENESIS LIPIDEMIA AND CLINICAL DIAGNOSIS OF STRESS ANGINA OF DIFFERENT FUNCTIONAL CLASSES | 2019 |
|
RU2721687C1 |
| METHOD FOR ASSESSING A POSSIBLE HIGH, MODERATE AND LOW RISK OF THROMBOGENIC COMPLICATIONS OF ISCHEMIC HEART DISEASE COURSE | 2019 |
|
RU2721877C1 |
| METHOD FOR ASSESSING PROGRESSION OF ATHEROGENICITY IN ISCHEMIC HEART DISEASE | 2013 |
|
RU2521322C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF LIPIDEMIA | 2013 |
|
RU2517054C1 |
| METHOD FOR EVALUATING CLINICAL EFFECTIVENESS IN LIPIDEMIA | 2011 |
|
RU2462718C1 |
| AGENT POSSESSING HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC ACTIVITY | 2015 |
|
RU2598347C1 |
| AGENT WITH HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC ACTION | 2008 |
|
RU2372897C1 |
